Martin Shkreli was head of Turing Pharmaceuticals — later Vyera — when it hiked the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. AP
Martin Shkreli was head of Turing Pharmaceuticals — later Vyera — when it hiked the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to the decades-old drug in 2015. AP

'Pharma Bro' Martin Shkreli ordered to return $64m in profits